Premium
Tandem high‐dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high‐risk medulloblastoma or supratentorial primitive neuro‐ectodermic tumors
Author(s) -
Dufour Christelle,
Kieffer Virginie,
Varlet Pascale,
Raquin Marie Anne,
Dhermain Frederic,
Puget Stephanie,
ValteauCouanet Dominique,
Grill Jacques
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25009
Subject(s) - medicine , medulloblastoma , thiotepa , chemotherapy , surgery , radiation therapy , oncology , pediatrics , pathology , cyclophosphamide
Background To assess the feasibility and effectiveness of high‐dose chemotherapy (HDC) with stem cell support followed by conventional craniospinal radiotherapy (RT) as treatment for children older than 5 years of age with newly diagnosed high‐risk medulloblastoma (MB) or supratentorial PNET (sPNET). Procedure Between May 2001 and April 2010, 24 children older than 5 years of age (MB = 21; sPNET = 3), fulfilling inclusion criteria at diagnosis, were treated at Gustave Roussy. After conventional chemotherapy, they received two courses of high‐dose thiotepa (600 mg/m 2 ) followed by craniospinal RT. Results The median follow‐up was 4.4 years (range, 0.8–11.3 years). For children with metastatic MB, the 5‐year event‐free survival (EFS) and overall survival (OS) were 72% and 83%, respectively. The toxicity was manageable. No toxic death occurred. At the most recent evaluation, among the 24 children who had at least one Full Scale Intellectual Quotient (FSIQ) examination at a median follow‐up of 3.79 years after diagnosis, the mean estimated FSIQ was 82 (range, 56–114). Conclusions In children with metastatic MB, tandem HDCT with ASCT followed by conventional craniospinal RT proved its feasibility without jeopardizing survival. Pediatr Blood Cancer 2014; 61:1398–1402. © 2014 Wiley Periodicals, Inc.